GB201615842D0 - Cell death biomarker - Google Patents

Cell death biomarker

Info

Publication number
GB201615842D0
GB201615842D0 GBGB1615842.0A GB201615842A GB201615842D0 GB 201615842 D0 GB201615842 D0 GB 201615842D0 GB 201615842 A GB201615842 A GB 201615842A GB 201615842 D0 GB201615842 D0 GB 201615842D0
Authority
GB
United Kingdom
Prior art keywords
cell death
biomarker
death biomarker
cell
death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1615842.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Priority to GBGB1615842.0A priority Critical patent/GB201615842D0/en
Publication of GB201615842D0 publication Critical patent/GB201615842D0/en
Priority to DK17771553.9T priority patent/DK3513192T3/da
Priority to JP2019514263A priority patent/JP7211936B2/ja
Priority to EP17771553.9A priority patent/EP3513192B1/en
Priority to US16/333,590 priority patent/US11789012B2/en
Priority to PCT/GB2017/052733 priority patent/WO2018051110A1/en
Priority to ES17771553T priority patent/ES2863274T3/es
Priority to AU2017327994A priority patent/AU2017327994B2/en
Priority to US18/299,415 priority patent/US20240118266A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1615842.0A 2016-09-16 2016-09-16 Cell death biomarker Ceased GB201615842D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1615842.0A GB201615842D0 (en) 2016-09-16 2016-09-16 Cell death biomarker
DK17771553.9T DK3513192T3 (da) 2016-09-16 2017-09-15 Celledødsbiomarkør
JP2019514263A JP7211936B2 (ja) 2016-09-16 2017-09-15 細胞死のバイオマーカー
EP17771553.9A EP3513192B1 (en) 2016-09-16 2017-09-15 Cell death biomarker
US16/333,590 US11789012B2 (en) 2016-09-16 2017-09-15 Cell death biomarker
PCT/GB2017/052733 WO2018051110A1 (en) 2016-09-16 2017-09-15 Cell death biomarker
ES17771553T ES2863274T3 (es) 2016-09-16 2017-09-15 Biomarcador de muerte celular
AU2017327994A AU2017327994B2 (en) 2016-09-16 2017-09-15 Cell death biomarker
US18/299,415 US20240118266A1 (en) 2016-09-16 2023-04-12 Cell death biomarker

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1615842.0A GB201615842D0 (en) 2016-09-16 2016-09-16 Cell death biomarker

Publications (1)

Publication Number Publication Date
GB201615842D0 true GB201615842D0 (en) 2016-11-02

Family

ID=57288813

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1615842.0A Ceased GB201615842D0 (en) 2016-09-16 2016-09-16 Cell death biomarker

Country Status (8)

Country Link
US (2) US11789012B2 (https=)
EP (1) EP3513192B1 (https=)
JP (1) JP7211936B2 (https=)
AU (1) AU2017327994B2 (https=)
DK (1) DK3513192T3 (https=)
ES (1) ES2863274T3 (https=)
GB (1) GB201615842D0 (https=)
WO (1) WO2018051110A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CN112961864A (zh) * 2021-02-26 2021-06-15 广州市妇女儿童医疗中心 突变的asxl3基因及应用
CN114478797B (zh) * 2021-11-24 2023-10-27 中山大学附属第五医院 一种靶向ddx24蛋白的水解靶向嵌合体及其应用
US12456104B2 (en) 2023-02-10 2025-10-28 linch Limited Dynamic multi-path transfers
CN117843657B (zh) * 2023-12-30 2025-08-05 新乡医学院 Brd4/nampt双靶向抑制剂及其作为抗肝癌药物的应用
US12608709B2 (en) 2024-03-15 2026-04-21 Degensoft Ltd. Decentralized systems and methods for response generation to API calls
US12574234B2 (en) 2024-04-18 2026-03-10 Degensoft Ltd Secure cross-chain atomic swaps

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20020169123A1 (en) 2001-02-27 2002-11-14 The Trustees Of The University Of Pennsylvania Regulating apoptosis in TRAIL-resistant cancer cells, while protecting normal, non-cancerous cells
NZ574009A (en) * 2006-06-20 2012-01-12 Genentech Inc Methods and materials for observing apoptosis by detecting fragments of clathrin-pathway components
WO2012040614A1 (en) * 2010-09-23 2012-03-29 The Washington University Compositions and methods for detecting cancer metastasis
AU2012364924A1 (en) * 2011-02-16 2013-09-12 Medical University Of Graz BAP1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia
JP6108571B2 (ja) 2013-03-28 2017-04-05 国立大学法人東北大学 食道癌の発症リスクを判定する方法及びキット
US9868736B2 (en) 2013-10-10 2018-01-16 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
US20160101071A1 (en) * 2014-04-28 2016-04-14 Wisconsin Alumni Research Foundation Combination cancer treatment
CA2948883A1 (en) 2014-06-02 2015-12-10 Pharmakea, Inc. Deubiquitinase inhibitors
SG11201610610YA (en) 2014-06-19 2017-01-27 Sloan Kettering Inst Cancer Biomarkers for response to ezh2 inhibitors

Also Published As

Publication number Publication date
DK3513192T3 (da) 2021-03-29
US20240118266A1 (en) 2024-04-11
AU2017327994A1 (en) 2019-04-04
AU2017327994B2 (en) 2023-09-14
JP7211936B2 (ja) 2023-01-24
EP3513192B1 (en) 2020-12-23
US20190257818A1 (en) 2019-08-22
WO2018051110A1 (en) 2018-03-22
JP2020500502A (ja) 2020-01-16
EP3513192A1 (en) 2019-07-24
US11789012B2 (en) 2023-10-17
ES2863274T3 (es) 2021-10-11

Similar Documents

Publication Publication Date Title
IL274903A (en) cell
ZA201707334B (en) Cell
GB201610515D0 (en) Cell
GB201507368D0 (en) Cell
GB201503500D0 (en) Cell
GB201514874D0 (en) Cell
GB201518817D0 (en) Cell
GB201621889D0 (en) Cell
GB201616238D0 (en) Modified T cells
GB201603372D0 (en) Cell
GB201615842D0 (en) Cell death biomarker
GB201409519D0 (en) Senescent cell biomarkers
ZA201900891B (en) B-cell-mimetic cells
GB201609604D0 (en) Cell
GB201617716D0 (en) Cell
GB201420239D0 (en) Biomarker
GB201416015D0 (en) Biomarker
IL252570A0 (en) in the colon of a small cell
PL3149792T3 (pl) Ogniwo litowo-siarkowe
GB201604427D0 (en) Modified cell
GB201513462D0 (en) Biomarkers for immunogenic cell death
GB201513459D0 (en) Biomarkers for immunogenic cell death
GB201607647D0 (en) Dilatometer cell
GB201521446D0 (en) Biomarker
GB201507812D0 (en) Cell

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)